1. Home
  2. NBIX vs BSAC Comparison

NBIX vs BSAC Comparison

Compare NBIX & BSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$174.19

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Banco Santander - Chile ADS

BSAC

Banco Santander - Chile ADS

HOLD

Current Price

$33.02

Market Cap

14.3B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
BSAC
Founded
1992
1977
Country
United States
Chile
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
14.3B
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
NBIX
BSAC
Price
$174.19
$33.02
Analyst Decision
Strong Buy
Hold
Analyst Count
22
3
Target Price
$180.91
$33.00
AVG Volume (30 Days)
1.1M
365.5K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
3.51%
EPS Growth
41.95
N/A
EPS
1.91
N/A
Revenue
$161,626,000.00
N/A
Revenue This Year
$24.73
$37.15
Revenue Next Year
$13.14
$7.52
P/E Ratio
$91.24
$14.40
Revenue Growth
977.51
N/A
52 Week Low
$122.14
$22.77
52 Week High
$174.38
$37.72

Technical Indicators

Market Signals
Indicator
NBIX
BSAC
Relative Strength Index (RSI) 67.99 57.38
Support Level $153.96 $31.65
Resistance Level N/A $33.12
Average True Range (ATR) 4.48 0.82
MACD 0.66 0.06
Stochastic Oscillator 95.56 59.63

Price Performance

Historical Comparison
NBIX
BSAC

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About BSAC Banco Santander - Chile ADS

Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.

Share on Social Networks: